Authors
Zepu Wang, Dan Lv, Hanxiang Yu, Chuncheng Wang, Yanhui Peng
Published in
Medicine. Volume 105. Issue 27. Pages e49614. Jul 03, 2026.
Abstract
This study aimed to evaluate the clinical efficacy of 3 jaundice reduction methods in patients with intermediate or advanced hilar cholangiocarcinoma (HCCA) at different Mayo stages. Clinical data from 223 patients with HCCA who underwent palliative jaundice reduction treatment were collected and analyzed retrospectively. A statistical analysis was conducted to compare the therapeutic effects, survival times, complications, and hospital stays of patients in the 3 groups with different Mayo stages. Survival curves were plotted for patients with different Mayo stages. There was no statistically significant difference in decreased liver enzyme and bilirubin levels among the 3 patient groups after surgery (P > .05). For patients at Mayo stages I and II, the median survival time for those who underwent palliative surgery was longer than for those who underwent percutaneous transhepatic biliary drainage (PTBD) or endoscopic biliary drainage (EBD) (P = .001 and P < .001, respectively). For patients at Mayo stages III and IV, however, there was no statistically significant difference in median survival time between the 3 groups (P > .05). There was also no statistically significant difference in the incidence of complications in each group at every stage (P > .05). Hospital stays for the palliative surgery group were significantly longer than for the PTBD and EBD groups (P < .001). For HCCA patients in Mayo stages I and II, palliative surgical treatment should be prioritized. For patients at Mayo stage III, EBD treatment is more appropriate. For patients in Mayo stage IV with poor general health, PTBD is a more appropriate choice.
PMID:
42410830
Bibliographic data and abstract were imported from PubMed on 07 Jul 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 8
- Comments 0